Who are Prednisolone and Tobramycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexamethasone+Tobramycin eye drop.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prednisolone-and-tobramycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Prednisolone and Tobramycin — Competitive Intelligence Brief

Prednisolone and Tobramycin (Prednisolone and Tobramycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Aminoglycoside antibiotic combination. Area: Ophthalmology.

phase 3 Corticosteroid + Aminoglycoside antibiotic combination Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Prednisolone and Tobramycin (Prednisolone and Tobramycin) — Bausch & Lomb Incorporated. This combination uses prednisolone to suppress inflammation and tobramycin to provide topical antimicrobial coverage, typically for ocular infections or inflammatory conditions.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prednisolone and Tobramycin TARGET	Prednisolone and Tobramycin	Bausch & Lomb Incorporated	phase 3	Corticosteroid + Aminoglycoside antibiotic combination
Dexamethasone+Tobramycin eye drop	Dexamethasone+Tobramycin eye drop	Azienda USL Reggio Emilia - IRCCS	marketed	Corticosteroid + aminoglycoside antibiotic combination	Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Aminoglycoside antibiotic combination class)

Bausch & Lomb Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prednisolone and Tobramycin — Competitive Intelligence Brief. https://druglandscape.com/ci/prednisolone-and-tobramycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab